top of page

Group

Public·10 members
Rezo Bragin
Rezo Bragin

Where To Buy Testosterone Cream



AndroGel is a controlled substance (CIII) because it contains testosterone that can be a target for people who abuse prescription medicines. Keep it in a safe place to protect it and never give it to anyone else. Selling or giving away this medicine may harm others and is against the law.




where to buy testosterone cream


DOWNLOAD: https://www.google.com/url?q=https%3A%2F%2Furlcod.com%2F2uezEz&sa=D&sntz=1&usg=AOvVaw3qy8IQaF1Y0lBYogE3XIJ-



Stringent safeguards in telemedicine have helped ensure that prescribing testosterone can happen only if all parties (doctor, patient, and pharmacy) remain in legal compliance with the guidelines imposed by the Drug Enforcement Administration (DEA).


We are fully compliant with all federal and state laws regarding the prescription and sale of testosterone. Our team has worked tirelessly to provide you with a safe, legal, and simple step-by-step process.


Testosterone cream is applied 1-2 times daily to the skin. Once applied, the testosterone passes into the blood stream where it increases serum testosterone concentrations.30 grams/1 month supply


The main androgen in the body is testosterone. Species of cells in the testis, ovary, and adrenal cortex produce endogenous testosterone. In the treatment of either congenital or acquired hypogonadism, testosterone is employed. The best exogenous androgen for the palliative therapy of breast cancer in postmenopausal women is testosterone. In 1938, testosterone was in use, and the FDA gave its approval in 1939. Since they have been used illegally, anabolic steroids, which are testosterone derivatives, are now considered controlled substances. In 1991, testosterone, along with a number of anabolic steroids, was designated as a restricted substance. AndroGel, a testosterone cream developed by Uniumed Pharmaceuticals in the US, received FDA approval in 2000 for the treatment of hypogonadism, a condition that frequently causes mood, energy, and sexual dysfunctions, as well as a number of injury-related conditions like those suffered by severe burn and accident victims. AndroGel, a very popular form of testosterone, is sold all over the world under a few less well-known brand/trade names, most notably Testogel (produced in the UK by Laboratoires Besins and distributed by Bayer), Testim (produced in the US by Auxilium Pharmaceuticals, Inc.), and several generic variations frequently marketed as testosterone cream or gel.


The target body regions for testosterone cream's transdermal delivery system are the same or very comparable to those for injections and other testosterone delivery methods. More specifically, testosterone cream absorbs best when applied to heavily muscled body parts, just like testosterone injections do. Since there are more testosterone-absorbing capillaries at the site of application when there is more muscle, testosterone can enter the bloodstream more quickly.


Sexual development occurs throughout life at all stages of development thanks to endogenous testosterone. It is made synthetically from cholesterol. Androgens play a significant part in the development of males from the time they are fetuses to adulthood. They are essential during puberty. Small amounts of testosterone are also secreted by females from their ovaries. Male sexuality cannot be sustained by the adrenal cortex's androgen release.


Through a negative-feedback mechanism, elevated androgen plasma concentrations inhibit gonadotropin-releasing hormone (which lowers endogenous testosterone), luteinizing hormone, and follicle-stimulating hormone. Additionally, the production of erythropoietin, the balance of calcium, and blood sugar are all impacted by testosterone. Androgens have a high lipid solubility, which allows them to reach target tissue cells quickly. When testosterone enters cells, it is enzymatically converted to 5-alpha-dihydrotestosterone and joins with cystolic receptors to create a loosely bound complex. The steroid-receptor complex causes cellular alterations in the nucleus and the start of transcription, which are the causes of androgen activity.


In addition to intramuscular injection (IM), subcutaneous injection, topical gel, solution, ointment, or transdermal devices for transdermal absorption, long-acting pellet implantation, or buccal systems are other ways to give testosterone.


Testosterone is protein-bound in serum. Compared to albumin, it exhibits a strong affinity for the sex hormone binding globulin (SHBG). The fraction that is attached to albumin separates readily. As people age, their affinity for SHBG changes. It peaks at puberty, falls off during adolescence and adulthood, and then increases once more in old age. Compared to testosterone, the active metabolite DHT has a stronger affinity for SHBG. The half-life of elimination ranges from 10 to 100 minutes and is influenced by the plasma concentration of free testosterone.


The liver is where testosterone is predominantly converted to several 17-keto steroids. Hepatic cytochrome P450 (CYP) 3A4 isoenzyme uses it as a substrate.1 The two main active metabolites are estradiol and dihydrotestosterone (DHT), and DHT is further metabolized. The production of DHT, which binds to cytosol receptor proteins, appears to be necessary for testosterone action. DHT is further metabolized in reproductive organs. An intramuscular testosterone dose is eliminated in the urine in around 90% of the form of glucuronic and sulfuric acid conjugates. The majority of the 6 percent expelled in the feces is unconjugated. The half-life of testosterone, as reported in the literature, varies significantly and can be anywhere from 10 and 100 minutes.2


Topical Route: With a once daily dose, around 10% of a topical testosterone skin gel or ointment application is absorbed systemically; the skin continues to absorb the gel and solution over the course of the following 24 hours, suggesting that the skin serves as a reservoir for sustained-release. Application of a testosterone solution or gel produces circulation levels of the hormone that are physiologically similar to those found in healthy males. 45 Steady-state concentrations are achieved after approximately 14 days of solution application; when the solution is stopped, pre-treatment testosterone concentrations are achieved in approximately 7 to 10 days.6


Your doctor needs to know if you have any of the following conditions: breast cancer, sleep apnea, diabetes, heart disease, kidney disease, liver disease, lung disease, prostate cancer or enlargement, any unusual or allergic reactions to testosterone or other medications, being pregnant or trying to become pregnant, or breastfeeding. While using testosterone, your doctor will need to have frequent bloodwork taken. Most athletic organizations forbid using this drug on athletes.


Male patients with prostate cancer or breast cancer should not use testosterone since it can promote the formation of malignant tissue. Prostatic hypertrophy patients should be treated carefully because androgen therapy may exacerbate the condition's signs and symptoms and raise the possibility of cancer developing. Prior to beginning testosterone replacement medication, elderly patients and other patients with clinical or demographic traits known to be linked to an elevated risk of prostate cancer should be assessed for the disease's existence. Prostate cancer surveillance in patients receiving testosterone therapy ought to follow existing guidelines for eugonadal men. Age-related hypogonadism alone in geriatric patients or andropause are not advised for testosterone replacement therapy because there is inadequate evidence of its safety and effectiveness.7 Furthermore, due to a dearth of elderly participants in controlled trials, the effectiveness and long-term safety of testosterone topical solution in patients older than 65 have not been established. 8 The Beers Criteria state that testosterone is a potentially inappropriate drug (PIM) for geriatric people and that it should be avoided since it may cause cardiac issues and is contraindicated in cases of prostate cancer. Use for moderate to severe hypogonadism is acceptable in the opinion of the Beers expert panel. 9


Patients with liver disease or malfunction should be given testosterone with caution due to decreased drug clearance and an increased risk of drug buildup. Additionally, edema brought on by sodium and water retention may develop while taking androgens for treatment. In individuals with hepatic disease, renal disease such as nephritis and nephrosis, preexisting edema, or cardiac disease such as heart failure, coronary artery disease, and myocardial infarction (MI), use testosterone with caution as fluid retention may exacerbate these symptoms. Further, regardless of pre-existing heart disease, research is being done into the potential link between testosterone usage and an increased risk of serious cardiovascular events. Adult male patients with an average age of 60 were included in an observational study at the U.S. Veterans Affairs medical system. Retrospective analysis comprised patients (n = 8779) undergoing coronary angiography with a documented low blood testosterone levels of less than 300 ng/dl. Within the larger group, 1223 guys underwent testosterone therapy after a median of 531 days had passed since coronary angiography; 7486 males did not. In the three years following coronary angiography, individuals taking testosterone therapy experienced a serious and/or fatal cardiovascular event at a rate of 25,7% compared to patients not receiving therapy at a rate of 19,9%. (MI, stroke, death).10 The incidence of acute non-fatal MI following a first testosterone prescription was examined in a second observational research (n = 55,593) in both younger (=55 years) and older (>=65 years) adult males. When compared to the incidence rate of MI happening in the year preceding the first testosterone prescription, the incidence rate of MI occurring 90 days after the first prescription was studied. There was a 2-fold increase in MI risk among older men during the 90-day window, and there was a 2- to 3-fold increase in MI risk among younger men with a history of cardiac disease. Younger men without a history of heart disease, in comparison, did not exhibit an elevated risk.11 In response to these findings, the FDA said in the beginning of 2014 that it will look into any potential associations between testosterone therapy and serious cardiovascular events. The FDA has not determined that testosterone therapy permitted by the agency raises the risk of stroke, MI, or demise. But healthcare practitioners are recommended to carefully examine whether the potential dangers outweigh the expected benefits of treatment. When the review is over, the FDA will announce its final results and suggestions.12 041b061a72


About

Welcome to the group! You can connect with other members, ge...

Members

bottom of page